Positron Emission Tomography-CT Imaging in Guiding Musculoskeletal Biopsy

Radiologic Clinics of North America

Volumn 46, Issue 3, 2008, Pages 475-486

  O'Sullivan, Paul J ^a   Rohren, Eric M ^a   Madewell, John E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biopsy; Musculoskeletal; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

AVASCULAR NECROSIS; BIOPSY; BONE LESION; CANCER DIAGNOSIS; CANCER STAGING; CELL HETEROGENEITY; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; FOLLOW UP; METASTASIS; MUSCULOSKELETAL BIOPSY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TUMOR NECROSIS;

ADOLESCENT; ADULT; BIOPSY, NEEDLE; BONE NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MUSCLE NEOPLASMS; MUSCULOSKELETAL SYSTEM; NECROSIS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 49149127245     PISSN: 00338389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rcl.2008.02.004     Document Type: Review

References (25)

1. Weihkopf T., Blettner M., Dantonello T., et al. Incidence and time trends of soft tissue sarcomas in German children 1985-2004-a report from the population-based German Childhood Cancer Registry. Eur J Cancer 44 3 (2008) 432-440
2. Larsson S.E., and Lorentzon R. The incidence of malignant primary bone tumors in relation to age, sex and site. A study of osteogenic sarcoma, chondrosarcoma and Ewing's sarcoma diagnosed in Sweden from 1958 to 1968. J Bone Joint Surg Br 56 (1974) 534-540
3. Damron T.A., Ward W.G., and Stewart A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: national cancer data base report. Clin Orthop Relat Res 459 (2007) 40-47
4. Bruzzi J.F., and Munden R.F. PET/CT imaging of lung cancer. J Thorac Imaging 21 (2006) 123-136
5. Bruzzi J.F., Munden R.F., Truong M.T., et al. PET/CT of esophageal cancer: its role in clinical management. Radiographics 27 (2007) 1635-1652
6. Konski A.A., Cheng J.D., Goldberg M., et al. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. Int J Radiat Oncol Biol Phys 69 (2007) 358-363
7. Truong M.T., Erasmus J.J., Macapinlac H.A., et al. Integrated positron emission tomography/computed tomography in patients with non-small cell lung cancer: normal variants and pitfalls. J Comput Assist Tomogr 29 (2005) 205-209
8. de Geus-Oei L.F., van Krieken J.H., Aliredjo R.P., et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 55 (2007) 79-87
9. Tomonaga T., Okuyama K., Nagao K., et al. [Retroperitoneal liposarcoma with various histological figures]. Gan No Rinsho 32 (1986) 927-932 [in Japanese]
10. Nguyen N.C., Chaar B.T., and Osman M.M. Prevalence and patterns of soft tissue metastasis: detection with true whole-body F-18 FDG PET/CT. BMC Med Imaging 12 (2007) 7-8
11. Suzuki R., Watanabe H., Yanagawa T., et al. PET evaluation of fatty tumors in the extremity: possibility of using the standardized uptake value (SUV) to differentiate benign tumors from liposarcoma. Ann Nucl Med 19 (2005) 661-670
12. Graadt van Roggen J.F., Hogendoorn P.C., and Fletcher C.D. Myxoid tumors of soft tissue. Histopathology 35 (1999) 291-312
13. Park H.S., Chung J.W., Jae H.J., et al. FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model. Korean J Radiol 8 (2007) 216-224
14. Kobayashi E., Kawai A., Seki K., et al. Bilateral adrenal gland metastasis from malignant fibrous histiocytoma: value of [F-18] FDG PET-CT for diagnosis of occult metastases. Ann Nucl Med 20 (2006) 695-698
15. Iagaru A., Chawla S., Menendez L., et al. 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. Nucl Med Commun 27 (2006) 795-802
16. Metser U., Miller E., Lerman H., et al. Benign nonphysiologic lesions with increased 18F-FDG uptake on PET/CT: characterization and incidence. AJR Am J Roentgenol 189 (2007) 1203-1210
17. Takahashi N., Inoue T., Lee J., et al. The roles of PET and PET/CT in the diagnosis and management of prostate cancer. Oncology 72 (2008) 226-233
18. Surti S., and Karp J.S. Imaging characteristics of a 3-dimensional GSO whole-body PET camera. J Nucl Med 45 (2004) 1040-1049
19. Beresford M., Lyburn I., Sanghera B., et al. Serial integrated (18) F-fluorodeoxythymidine PET/CT monitoring neoadjuvant chemotherapeutic response in invasive ductal carcinoma. Breast J 13 (2007) 424-425
20. Hutchings M., Mikhaeel N.G., Fields P.A., et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16 (2005) 1160-1168
21. Soudack M., Shalom R.B., Israel O., et al. Utility of sonographically guided biopsy in metabolically suspected recurrent lymphoma. J Ultrasound Med 27 (2008) 225-231
22. Schaefer N.G., Taverna C., Strobel K., et al. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy-is biopsy of FDG-avid lesions still needed?. Radiology 244 (2007) 257-262
23. Schaefer N.G., Strobel K., Taverna C., et al. Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging 34 (2007) 60-67
24. Clarke J.R., Brglevska S., Lau E.W., et al. Atypical brown fat distribution in young males demonstrated on PET/CT. Clin Nucl Med 32 (2007) 679-682
25. Raylman R.R., Majewski S., Smith M.F., et al. The positron emission mammography/tomography breast imaging and biopsy system (PEM/PET): design, construction and phantom-based measurements. Phys Med Biol 53 (2008) 637-653